Hepato-cardiac disorders

World Journal of Hepatology

Volumn 6, Issue 1, 2014, Pages 41-54

  Fouad, Yasser Mahrous ^a   Yehia, Reem ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Cardiac cirrhosis; Fatty liver; Heart failure; Ischemic hepatitis; Liver cirrhosis

Indexed keywords

EID: 84893643316     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i1.41     Document Type: Review

References (135)

1. Khadem E, Nasiri Toosi M, Ilkhani R. Liver- Heart Inter- Relationship in Fatty Liver Disease Based on the Avicenna's Point of View. Iran J Public Health 2013; 42: 648-649 [PMID: 23967437]
2. Avicenna. Al Qanun Fi Al-Tibb (Arabic). Beirut: Alaalami library, 2005: 128-129
3. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23: 1128-1134 [PMID: 8621144 DOI: 10.1002/hep.510230529]
4. Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, Chalasani N. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol 2005; 95: 691-694 [PMID: 15721125 DOI: 10.1016/j.amjcard.2004.10.054]
5. Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist's point of view. Int J Cardiol 2013; 166: 554-558 [PMID: 22656043 DOI: 10.1016/j.ijcard.2012.05.003]
6. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 2005; 96: 144-147 [PMID: 15692092 DOI: 10.1161/01.RES.0000156077.54903.67]
7. Omura T, Yoshiyama M, Hayashi T, Nishiguchi S, Kaito M, Horiike S, Fukuda K, Inamoto S, Kitaura Y, Nakamura Y, Teragaki M, Tokuhisa T, Iwao H, Takeuchi K, Yoshikawa J. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res 2005; 96: 148-150 [PMID: 15618537 DOI: 10.1161/01.RES.0000154263.70223.13]
8. Terrier B, Karras A, Cluzel P, Collet JP, Sène D, Saadoun D, Cacoub P. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol 2013; 111: 265-272 [PMID: 23116612 DOI: 10.1016/j.amjcard.2012.09.028]
9. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013; 37: 647-652
10. Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, Imaizumi T, Sata M. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol 2013; 48: 93-100 [PMID: 22678465 DOI: 10.1007/s00535-012-0610-3]
11. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221: 496-502 [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051]
12. Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-423 [PMID: 23802888 DOI: 10.1111/apt.12391]
13. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, Masini A, De Castro S, Merli M. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000; 95: 3200-3205 [PMID: 11095342 DOI: 10.1111/j.1572-0241.2000.03252.x]
14. Ates F, Topal E, Kosar F, Karincaoglu M, Yildirim B, Aksoy Y, Aladag M, Harputluoglu MM, Demirel U, Alan H, Hilmioglu F. The relationship of heart rate variability with severity and prognosis of cirrhosis. Dig Dis Sci 2006; 51: 1614-1618 [PMID: 16927142 DOI: 10.1007/s10620-006-9073-9]
15. Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. Lancet 1992; 339: 1462-1464 [DOI: 10.1016/0140-6736(92)92042-E]
16. Milan A, Caserta MA, Del Colle S, Dematteis A, Morello F, Rabbia F, Mulatero P, Pandian NG, Veglio F. Baroreflex sensitivity correlates with left ventricular morphology and diastolic function in essential hypertension. J Hypertens 2007; 25: 1655-1664 [PMID: 17620963 DOI: 10.1097/HJH.0b013e3281ddb0a0]
17. Lantelme P, Khettab F, Custaud MA, Rial MO, Joanny C, Gharib C, Milon H. Spontaneous baroreflex sensitivity: toward an ideal index of cardiovascular risk in hypertension? J Hypertens 2002; 20: 935-944 [PMID: 12011655 DOI: 10.1097/00004872-200205000-00029]
18. Okada N, Takahashi N, Yufu K, Murozono Y, Wakisaka O, Shinohara T, Anan F, Nakagawa M, Hara M, Saikawa T, Yoshimatsu H. Baroreflex sensitivity predicts cardiovascular events in patients with type 2 diabetes mellitus without structural heart disease. Circ J 2010; 74: 1379-1383 [PMID: 20453396 DOI: 10.1253/circj.CJ-09-0960]
19. Yufu K, Takahashi N, Okada N, Wakisaka O, Shinohara T, Nakagawa M, Hara M, Yoshimatsu H, Saikawa T. Gender difference in baroreflex sensitivity to predict cardiac and cerebrovascular events in type 2 diabetic patients. Circ J 2011; 75: 1418-1423 [PMID: 21478631 DOI: 10.1253/circj.CJ-10-1122]
20. Mircoli L, Rivera R, Bonforte G, Fedele L, Genovesi S, Surian M, Ferrari AU. Influence of left ventricular mass, uremia and hypertension on vagal tachycardic reserve. J Hypertens 2003; 21: 1547-1553 [PMID: 12872050 DOI: 10.1097/00004872-200308000-00020]
21. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15 [PMID: 11751653 DOI: 10.1136/heart.87.1.9]
22. Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 1995; 107: 1467-1469 [PMID: 7750353 DOI: 10.1378/chest.107.5.1467]
23. Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-278 [PMID: 18192456 DOI: 10.1136/gut.2006.112177]
24. Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013; 34: 2804-2811 [PMID: 23853073 DOI: 10.1093/eurheartj/eht246]
25. Gaskari SA, Honar H, Lee SS. Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 329-337 [PMID: 16741552 DOI: 10.1038/ncpgasthep0498]
26. Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53: 1135-1145 [PMID: 20850887 DOI: 10.1016/j.jhep.2010.08.001]
27. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294-304 [PMID: 19669380 DOI: 10.1007/s12072-008-9109-7]
28. Wong F, Villamil A, Merli M, Romero G, Angeli P, Caraceni P, Steib CJ, Baik SK, Spinzi G, Colombato LA, Salerno F. Prevalence of diastolic dysfunction in cirrhosis and its clinical significance. Hepatology 2011; 54 Suppl 1, A475-A476
29. Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-586 [PMID: 9247479 DOI: 10.1053/gast.1997.v113.pm9247479]
30. Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, Albillos A, Jiménez W, Arroyo V. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-1218 [PMID: 14578859 DOI: 10.1053/jhep.2003.50447]
31. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, Jiménez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447 [PMID: 15977202 DOI: 10.1002/hep.20766]
32. Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol 2012; 6: 57-66 [PMID: 22149582 DOI: 10.1586/egh.11.86]
33. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J, Genescà J. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68-74 [PMID: 15629509 DOI: 10.1016/j.jhep.2004.09.008]
34. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 Suppl 1: S40-S43 [PMID: 19381123]
35. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011; 56: 35-45 [PMID: 20464495 DOI: 10.1007/s10620-010-1241-2]
36. Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010; 28: 210-213 [PMID: 20460913 DOI: 10.1159/000282088]
37. Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, Chiesa C. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2013; Epub ahead of print [PMID: 23843206 DOI: 10.1002/hep.26610]
38. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007; 46: 1131-1137 [PMID: 17685473 DOI: 10.1002/hep.21795]
39. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 1044-1051 [PMID: 12360466 DOI: 10.1053/gast.2002.36027]
40. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 1999; 45: 756-760 [PMID: 10517916 DOI: 10.1136/gut.45.5.756]
41. Parati G, Di Rienzo M, Mancia G. Dynamic modulation of baroreflex sensitivity in health and disease. Ann N Y Acad Sci 2001; 940: 469-487 [PMID: 11458702 DOI: 10.1111/j.1749-6632.2001.tb03699.x]
42. Schwartz PJ. The autonomic nervous system and sudden death. Eur Heart J 1998; 19 Suppl F: F72-F80 [PMID: 9651739]
43. Hollingsworth KG, Newton JL, Taylor R, McDonald C, Palmer JM, Blamire AM, Jones DE. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol 2008; 6: 1041-1048 [PMID: 18691944 DOI: 10.1016/j.cgh.2008.04.013]
44. Jones DE, Hollingsworth K, Fattakhova G, MacGowan G, Taylor R, Blamire A, Newton JL. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G764-G773 [PMID: 20133949 DOI: 10.1152/ajpgi.00501.2009]
45. Fickert P, Moustafa T, Trauner M. Primary sclerosing cholangitis-- the arteriosclerosis of the bile duct? Lipids Health Dis 2007; 6: 3 [PMID: 17254334 DOI: 10.1186/1476-511X-6-3]
46. Agelopoulou P, Kapatais A, Varounis C, Grassos C, Kalkandi E, Kouris N, Pierakeas N, Babalis D. Hepatocellular carcinoma with invasion into the right atrium. Report of two cases and review of the literature. Hepatogastroenterology 2007; 54: 2106-2108 [PMID: 18251169]
47. Lin TY, Chiu KM, Chien CY, Wang MJ, Chu SH. Case 1. Right ventricular outflow obstruction caused by metastatic hepatocellular carcinoma. J Clin Oncol 2004; 22: 1152-1153 [PMID: 15020617 DOI: 10.1200/JCO.2004.04.151]
48. Saïsse J, Hardwigsen J, Castellani P, Caus T, Le Treut YP. Budd-Chiari syndrome secondary to intracardiac extension of hepatocellular carcinoma. Two cases treated by radical resection. Hepatogastroenterology 2001; 48: 836-839 [PMID: 11462935]
49. Liu YC, Ho YL, Huang GT, Chen DS, Sheu JC, Chen CH. Clinical manifestations and survival of patients with hepatocellular carcinoma and cardiac metastasis. J Gastroenterol Hepatol 2010; 25: 150-155 [PMID: 19929928 DOI: 10.1111/j.1440-1746.2009.06036.x]
50. Hayashi N, Yasunori H, Soma I, Fukuchi N, Izawa H, Yoshida T, Ebisui C, Sakita I, Koshino T, Izumiyama K, Takeda Y, Fujimoto T. [Non-surgical treatment of hepatocellular carcinoma with tumor thrombus in the right atrium]. Gan To Kagaku Ryoho 2004; 31: 1918-1920 [PMID: 15553759]
51. Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998; 28: 1191-1198 [PMID: 9794901 DOI: 10.1002/hep.510280505]
52. Zhang QQ, Zu MH, Xu H, Gu YM, Wang WL, Gao ZK. Combining angioplasty with percutaneous microwave ablation for treating primary Budd-Chiari syndrome associated with hepatocellular carcinoma in two patients: A case report. Oncol Lett 2013; 6: 612-616 [PMID: 24137380]
53. Matsui S, Ichida T, Watanabe M, Sugitani S, Suda T, Takahashi T, Asakura H. Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection. J Gastroenterol Hepatol 2000; 15: 1205-1211 [PMID: 11106103]
54. Kew MC, McKnight A, Hodkinson J, Bukofzer S, Esser JD. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern African blacks. Hepatology 1989; 9: 121-125 [PMID: 2461892]
55. Shrestha SM. Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava. Hepatol Int 2009; 3: 392-402 [PMID: 19669366]
56. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Pulmonary- Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880 [PMID: 15516683 DOI: 10.1183/09031936.04.00010904]
57. Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, Ottobrelli A, Cerutti E, Polizzi S, Bucca C. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998; 129: 375-378 [PMID: 9735065 DOI: 10.7326/0003-4819-129-5-199809010-00005]
58. Zhang J, Yang W, Luo B, Hu B, Maheshwari A, Fallon MB. The role of CX3CL1/CX3CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome. J Hepatol 2012; 57: 752-758 [PMID: 22659346 DOI: 10.1016/j.jhep.2012.05.014]
59. Palma DT, Philips GM, Arguedas MR, Harding SM, Fallon MB. Oxygen desaturation during sleep in hepatopulmonary syndrome. Hepatology 2008; 47: 1257-1263 [PMID: 18311748 DOI: 10.1002/hep.22143]
60. McAdams HP, Erasmus J, Crockett R, Mitchell J, Godwin JD, McDermott VG. The hepatopulmonary syndrome: radiologic findings in 10 patients. AJR Am J Roentgenol 1996; 166: 1379-1385 [PMID: 8633451 DOI: 10.2214/ajr.166.6.8633451]
61. Martínez GP, Barberà JA, Visa J, Rimola A, Paré JC, Roca J, Navasa M, Rodés J, Rodriguez-Roisin R. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001; 34: 651-657 [PMID: 11434610 DOI: 10.1016/S0168-8278(00)00108-2]
62. Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Müller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125: 1042-1052 [PMID: 14517788 DOI: 10.1016/S0016-5085(03)01207-1]
63. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41: 1122-1129 [PMID: 15828054 DOI: 10.1002/hep.20658]
64. De BK, Dutta D, Pal SK, Gangopadhyay S, Das Baksi S, Pani A. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol 2010; 24: 183-188 [PMID: 20352147]
65. Rodríquez-Roisin R, Krowka MJ, Hervé P, Fallon MB. Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). J Hepatol 2005; 42: 924-927 [PMID: 15973780 DOI: 10.1016/j.jhep.2005.03.002]
66. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006; 44: 1502-1510 [PMID: 17133488 DOI: 10.1002/hep.21431]
67. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS, Fallon MB. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196-203 [PMID: 18537192 DOI: 10.1002/hep.22275]
68. Dickinson MG, Bartelds B, Borgdorff MA, Berger RM. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol 2013; 305: L1-14 [PMID: 23624788 DOI: 10.1152/ajplung.00031.2013]
69. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498 [PMID: 1991908 DOI: 10.1016/S0735-1097(10)80121-4]
70. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112: 980-986 [PMID: 9377962 DOI: 10.1378/chest.112.4.980]
71. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow- up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875-885 [PMID: 17539008 DOI: 10.1002/lt.21174]
72. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30: 1096-1102 [PMID: 17652314 DOI: 10.1183/09031936.00032407]
73. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, Seeger W, Ghofrani HA. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563-567 [PMID: 16807265 DOI: 10.1183/09031936.06.00030206]
74. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126 [PMID: 16401475 DOI: 10.1053/j.gastro.2005.10.013]
75. Malagari K, Nikita A, Alexopoulou E, Brountzos E, Papathanasiou M, Mitromaras J, Zakynthinos E, Papiris S, Kelekis DA. Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients. Hepatogastroenterology 2005; 52: 558-562 [PMID: 15816477]
76. Benet A, Vidal F, Toda R, Siurana R, De Virgala CM, Richart C. Diagnosis of hepatic hydrothorax in the absence of ascites by intraperitoneal injection of 99m-Tc-Fluor colloid. Postgrad Med J 1992; 68: 153 [PMID: 1570266 DOI: 10.1136/pgmj.68.796.153]
77. Gurung P, Goldblatt M, Huggins JT, Doelken P, Nietert PJ, Sahn SA. Pleural fluid analysis and radiographic, sonographic, and echocardiographic characteristics of hepatic hydrothorax. Chest 2011; 140: 448-453 [PMID: 21273292 DOI: 10.1378/chest.10-2134]
78. Xiol X, Castellví JM, Guardiola J, Sesé E, Castellote J, Perelló A, Cervantes X, Iborra MJ. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 1996; 23: 719-723 [PMID: 8666323 DOI: 10.1002/hep.510230410]
79. Orman ES, Lok AS. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009; 3: 582-586 [PMID: 19669710 DOI: 10.1007/s12072-009-9136-z]
80. Liu LU, Haddadin HA, Bodian CA, Sigal SH, Korman JD, Bodenheimer HC, Schiano TD. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004; 126: 142-148 [PMID: 15249455 DOI: 10.1378/chest.126.1.142]
81. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rössle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13: 529-534 [PMID: 11396532 DOI: 10.1097/00042737-200105000-00011]
82. Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, LoCicero J, Lewis WD, Jenkins RL, Trey C. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25: 1366-1369 [PMID: 9185754 DOI: 10.1002/hep.510250611]
83. Milanez de Campos JR, Filho LO, de Campos Werebe E, Sette H, Fernandez A, Filomeno LT, Jatene FB. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000; 118: 13-17 [PMID: 10893352 DOI: 10.1378/chest.118.1.13]
84. Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, Fix OK, Kay N, Abecassis MI, Gheorghiade M, Flaherty JD. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58: 223-231 [PMID: 21737011 DOI: 10.1016/j.jacc.2011.03.026]
85. Mandell MS, Lindenfeld J, Tsou MY, Zimmerman M. Cardiac evaluation of liver transplant candidates. World J Gastroenterol 2008; 14: 3445-3451 [PMID: 18567069 DOI: 10.3748/wjg.14.3445]
86. Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003; 37: 393-400 [PMID: 12540790 DOI: 10.1053/jhep.2003.50062]
87. Safran AP, Schaffner F. Chronic passive congestion of the liver in man. Electron microscopic study of cell atrophy and intralobular fibrosis. Am J Pathol 1967; 50: 447-463 [PMID: 6018673]
88. Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265: 174-189 [PMID: 4573728 DOI: 10.1097/00000441-197303000-00001]
89. Cogger VC, Fraser R, Le Couteur DG. Liver dysfunction and heart failure. Am J Cardiol 2003; 91: 1399 [PMID: 12767448 DOI: 10.1016/S0002-9149(03)00370-9]
90. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21: 1232-1237 [PMID: 7737628]
91. SHERLOCK S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951; 13: 273-293 [PMID: 14848381 DOI: 10.1136/hrt.13.3.273]
92. Lefkowitch JH, Mendez L. Morphologic features of hepatic injury in cardiac disease and shock. J Hepatol 1986; 2: 313-327 [PMID: 3722787 DOI: 10.1016/S0168-8278(86)80043-5]
93. Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. Clin Liver Dis 2011; 15: 1-20 [PMID: 21111990 DOI: 10.1016/j.cld.2010.09.010]
94. Henrion J, Minette P, Colin L, Schapira M, Delannoy A, Heller FR. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999; 29: 427-433 [PMID: 9918919 DOI: 10.1002/hep.510290202]
95. Mathurin P, Durand F, Ganne N, Mollo JL, Lebrec D, Degott C, Erlinger S, Benhamou JP, Bernuau J. Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology 1995; 109: 1682-1684 [PMID: 7557154 DOI: 10.1016/0016-5085(95)90659-2]
96. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003; 82: 392-406 [PMID: 14663289 DOI: 10.1097/01.md.0000101573.54295.bd]
97. ELLENBERG M, OSSERMAN KE. The role of shock in the production of central liver cell necrosis. Am J Med 1951; 11: 170-178 [PMID: 14856985]
98. KILLIP T, PAYNE MA. High serum transaminase activity in heart disease. Circulatory failure and hepatic necrosis. Circulation 1960; 21: 646-660 [PMID: 14409072 DOI: 10.1161/01.CIR.21.5.646]
99. CLARKE WT. Centrilobular hepatic necrosis following cardiac infarction. Am J Pathol 1950; 26: 249-255 [PMID: 15406254]
100. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109: 109-113 [PMID: 10967151]
101. Birgens HS, Henriksen J, Matzen P, Poulsen H. The shock liver. Clinical and biochemical findings in patients with centrilobular liver necrosis following cardiogenic shock. Acta Med Scand 1978; 204: 417-421 [PMID: 717063]
102. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol 2011; 20: 135-142 [PMID: 22942628 DOI: 10.1055/s-0031-1284434]
103. Caraceni P, Bianchi C, Domenicali M, Maria Pertosa A, Maiolini E, Parenti Castelli G, Nardo B, Trevisani F, Lenaz G, Bernardi M. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol 2004; 41: 82-88 [PMID: 15246212 DOI: 10.1016/j.jhep.2004.03.022]
104. Gitlin N, Serio KM. Ischemic hepatitis: widening horizons. Am J Gastroenterol 1992; 87: 831-836 [PMID: 1615936]
105. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994; 19: 118-121 [PMID: 7963356 DOI: 10.1097/00004836-199409000-00008]
106. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1-194 [PMID: 20610207 DOI: 10.1016/j.cardfail.2010.04.004]
107. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 1987; 4: 330-336 [PMID: 3298415 DOI: 10.1016/S0168-8278(87)80542-1]
108. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997; 62: 272-278 [PMID: 9333102]
109. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902 [PMID: 9421695]
110. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311 [PMID: 9257084]
111. Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38: 347-356 [PMID: 9590462]
112. Kirch W, Schafer-Korting M, Mutschler E, Ohnhaus EE, Braun W. Clinical experience with atenolol in patients with chronic liver disease. J Clin Pharmacol 1983; 23: 171-177 [PMID: 6863581 DOI: 10.1002/j.1552-4604.1983.tb02721.x]
113. Buchi KN, Rollins DE, Tolman KG, Achari R, Drissel D, Hulse JD. Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol 1987; 27: 880-884 [PMID: 3323260 DOI: 10.1002/j.1552-4604.1987.tb05583.x]
114. Zaman R, Jack DB, Wilkins MR, Kendall MJ. Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study. Biopharm Drug Dispos 1985; 6: 131-137 [PMID: 4005393 DOI: 10.1002/bdd.2510060204]
115. Fredrick MJ, Pound DC, Hall SD, Brater DC. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther 1991; 49: 241-247 [PMID: 2007318 DOI: 10.1038/clpt.1991.23]
116. Garguichevich JJ, Ramos JL, Gambarte A, Gentile A, Hauad S, Scapin O, Sirena J, Tibaldi M, Toplikar J. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995; 130: 494-500 [PMID: 7661066]
117. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006; 296: 2105-2111 [PMID: 17077375 DOI: 10.1001/jama.296.17.2105]
118. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell CT, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009; 120: 2352-2357 [PMID: 19933938 DOI: 10.1161/CIRCULATIONAHA.108.814863]
119. Dichtl W, Vogel W, Dunst KM, Grander W, Alber HF, Frick M, Antretter H, Laufer G, Pachinger O, Pölzl G. Cardiac hepatopathy before and after heart transplantation. Transpl Int 2005; 18: 697-702 [PMID: 15910296 DOI: 10.1111/j.1432-2277.2005.00122.x]
120. Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg 1999; 67: 723-730 [PMID: 10215217 DOI: 10.1016/S0003-4975(99)00042-9]
121. Wadia Y, Etheridge W, Smart F, Wood RP, Frazier OH. Pathophysiology of hepatic dysfunction and intrahepatic cholestasis in heart failure and after left ventricular assist device support. J Heart Lung Transplant 2005; 24: 361-370 [PMID: 15797736 DOI: 10.1016/j.healun.2004.09.012]
122. Yang JA, Kato TS, Shulman BP, Takayama H, Farr M, Jorde UP, Mancini DM, Naka Y, Schulze PC. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. J Heart Lung Transplant 2012; 31: 601-610 [PMID: 22458997 DOI: 10.1016/j.healun.2012.02.027]
123. Crespo-Leiro MG, Robles O, Paniagua MJ, Marzoa R, Naya C, Flores X, Suárez F, Gómez M, Grille Z, Cuenca JJ, Castro-Beiras A, Arnal F. Reversal of cardiac cirrhosis following orthotopic heart transplantation. Am J Transplant 2008; 8: 1336-1339 [PMID: 18444927 DOI: 10.1111/j.1600-6143.2008.02227.x]
124. Chokshi A, Cheema FH, Schaefle KJ, Jiang J, Collado E, Shahzad K, Khawaja T, Farr M, Takayama H, Naka Y, Mancini DM, Schulze PC. Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction. J Heart Lung Transplant 2012; 31: 591-600 [PMID: 22458996 DOI: 10.1016/j.healun.2012.02.008]
125. Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol 2011; 25: 445-448 [PMID: 21912770]
126. Te HS, Anderson AS, Millis JM, Jeevanandam V, Jensen DM. Current state of combined heart-liver transplantation in the United States. J Heart Lung Transplant 2008; 27: 753-759 [PMID: 18582805 DOI: 10.1016/j.healun.2008.04.004]
127. Ciocca M, Alvarez F. [Alagille syndrome]. Arch Argent Pediatr 2012; 110: 509-515 [PMID: 23224309 DOI: 10.1590/S0325-00752012000600009]
128. Zubiaurre L, Zapata E, Bujanda L, Castillo M, Oyarzabal I, Gutiérrez-Stampa MA, Cosme A. Cytomegalovirus hepatitis and myopericarditis. World J Gastroenterol 2007; 13: 647-648 [PMID: 17278238]
129. Elkiran O, Karakurt C, Selimoglu A, Karabiber H, Kocak G, Celik SF, Colak C. Subclinical diastolic dysfunction in children with Wilson's disease assessed by tissue Doppler echocardiography: a possible early predictor of cardiac involvement. Acta Cardiol 2013; 68: 181-187 [PMID: 23705561]
130. Hlubocká Z, Marecek Z, Linhart A, Kejková E, Pospísilová L, Martásek P, Aschermann M. Cardiac involvement in Wilson disease. J Inherit Metab Dis 2002; 25: 269-277 [PMID: 12227457 DOI: 10.1023/A:1016546223327]
131. Licata A, Brucato V, Di Marco V, Barbaria F, Craxì A. [Iron overload disease: recent findings]. Ann Ital Med Int 2004; 19: 145-154 [PMID: 15529941]
132. Giakoustidis A, Cherian TP, Antoniadis N, Giakoustidis D. Combined cardiac surgery and liver transplantation: three decades of worldwide results. J Gastrointestin Liver Dis 2011; 20: 415-421 [PMID: 22187708]
133. Hegazi MO, Ahmed S. Atypical clinical manifestations of graves' disease: an analysis in depth. J Thyroid Res 2012; 2012: 768019 [PMID: 22132347 DOI: 10.1155/2012/768019]
134. Estruch R, Fernández-Solá J, Sacanella E, Paré C, Rubin E, Urbano-Márquez A. Relationship between cardiomyopathy and liver disease in chronic alcoholism. Hepatology 1995; 22: 532-538 [PMID: 7635421]
135. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]